To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38064245.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2787.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient's response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS. See related article by Gleason et al., p. 703.
Medical subject headings
- Liposarcoma